Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer (Q58849543)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

main subject

metastatic breast cancer

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

F Montemurro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

S Spazzapan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

G Metro

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

J Foglietta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

G Bisagni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

A Ferzi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

R R Silva

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

T Gamucci

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

M Clavarezza

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

L Stocchi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

A Fabi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

F Cognetti

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

E Torrisi

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

D Crivellari

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

29 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

1436-1441

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR474

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDR474

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22039084%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference